DoD Prostate Cancer, Idea Development Award | HT9425 23 PCRP IDA

Opportunity Information: Apply for HT9425 23 PCRP IDA

The DoD Prostate Cancer Research Program (PCRP) FY23 Idea Development Award is built to fund fresh, high-risk, high-reward concepts in prostate cancer research that could meaningfully push the field forward. The central expectation is that the project is truly innovative, meaning it introduces a new way of thinking, challenges an established assumption, applies a creative method to a persistent problem, or leverages a special population or dataset in a novel way. Proposals that mainly extend previously published work in a straightforward, incremental manner are not considered a strong fit. The opportunity also signals strong interest in multidisciplinary projects and data science driven approaches, reflecting the program's push for teams that combine different skill sets to tackle complex prostate cancer questions.

A second core requirement is impact. Applicants must clearly connect their idea to at least one of the FY23 PCRP Overarching Challenges and explain how the work could provide a solution or a credible path toward one. Reviewers are looking for a convincing description of how the project could matter in both the near term and the longer term, whether by advancing fundamental understanding, improving diagnosis or risk stratification, shaping treatment decisions, or ultimately improving patient outcomes. In other words, novelty alone is not enough; the proposal needs a strong rationale for why the idea, if it works, could significantly advance prostate cancer research and/or patient care.

Preliminary data are encouraged but not required, which is important because it lowers the barrier for genuinely new ideas that may not yet have extensive supporting results. If preliminary findings are included, they should come from the PI's lab or from members of the project team, and they can be unpublished. Even without preliminary data, the application still needs to rest on a sound scientific rationale grounded in logical reasoning and a careful reading of existing literature. The announcement also highlights practical expectations that strengthen rigor and translational value, such as authenticating cell lines, applying statistical rigor in animal studies and epidemiology, building in experiments that test clinical relevance, and validating findings in patient cohorts when appropriate. If the project depends on specialized resources (for example, unique biospecimens, databases, or platforms), the program encourages letters of support to document access and availability.

The mechanism includes a specific New Investigator category aimed at researchers early in their independent careers. This category is designed to help launch new faculty or investigators building independence, but it comes with a key condition: applicants must include at least one collaborator with demonstrated prostate cancer expertise, shown through a track record of funding and publications. The application should explain how the collaboration will work, why it is likely to succeed, and how it strengthens the science by filling gaps in the PI's experience. A letter of collaboration describing the collaborator's role is strongly encouraged, and New Investigator applicants must meet the eligibility requirements described in the full announcement.

Team science is explicitly supported. Multidisciplinary and multi-institutional projects are allowed, but they must include a clear coordination plan explaining how team members will communicate, share data, manage progress, and integrate results across sites. For multi-institutional proposals, an intellectual property plan is also required to prevent institutional barriers from undermining collaboration and to address ownership and material transfer issues upfront.

Human subjects research is permitted, but clinical trials are not allowed. The program draws a bright line between observational clinical research (which is allowed) and clinical trials (which are not). In practice, that means studies using patient data or specimens, biomarker and imaging research, mechanism of disease studies, health disparities work, epidemiology, behavioral studies, and outcomes/health services research can be acceptable as long as they do not prospectively assign participants to an intervention to measure its effects. Correlative studies tied to an existing clinical trial are particularly encouraged, which is a way to extract additional scientific value from trials that are already underway without launching a new interventional study under this award. Any prospective human research must be no greater than minimal risk as determined by the IRB and DoD human research oversight.

Regulatory oversight requirements are a major operational consideration. DoD funded work involving human data, specimens, or subjects requires review not only by a local IRB/ethics committee but also by the USAMRDC Office of Human and Animal Research Oversight (OHARO), specifically the Office of Human Research Oversight (OHRO), before the study can begin. Local IRB approval is not required at the time of application, but it is required before OHRO review, and the DoD review can take up to around three months once complete documentation is submitted. For multi-site, non-exempt cooperative research within the U.S., applicants must plan for a single IRB arrangement under federal regulations, identifying the lead institution responsible for the master protocol and consent materials and serving as the main regulatory point of contact.

Animal research is also allowed, but it must undergo both local IACUC review and additional DoD level review through ACURO (the Animal Care and Use Review Office) before work starts. IACUC approval is not required at submission, but investigators should plan for DoD review timelines, commonly three to four months. The program strongly emphasizes reproducibility and transparent reporting for preclinical studies, pointing applicants to widely used rigor standards such as randomization, blinding, sample size estimation, and careful data handling, and encourages alignment with ARRIVE guidelines for animal research reporting.

From a funding and administrative standpoint, awards are issued as assistance agreements, meaning they may be grants or cooperative agreements depending on how much substantial involvement the DoD anticipates having during performance. If the agency expects minimal involvement, it is typically a grant; if collaboration or ongoing programmatic involvement is expected, it may be a cooperative agreement with those roles spelled out in the award. The direct cost budget for the full performance period is expected not to exceed $900,000. The program planned roughly $36 million total to support about 25 awards, with awards anticipated no later than September 30, 2024, and FY23 funds expected to remain available for use through September 30, 2029 (which matters for the government's obligation and spending window, not necessarily the length of each project).

Strategically, the opportunity aligns with broader DoD and congressional interest in accelerating progress for advanced and recurrent disease, including recommendations from the Metastatic Cancer Task Force, which applicants are encouraged to consult when shaping ideas that fit the FY23 priorities. The DoD also encourages collaborations between military or Veterans institutions and non-military partners, highlighting the value of combining infrastructure, expertise, and access to unique patient populations to generate findings that matter to Service members, Veterans, and the general public.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 03, 2023.
• Applicants must submit their applications by Jul 20, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 25 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 PCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: